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ABSTRACT Nucleic acid biopharmaceuticals are being investigated as potential therapeutics. 
They need to be incorporated into a bio-compatible carrier so as to overcome several biological 
barriers. Rational development of suitable nanocarriers requires high quality characterization 
techniques. While size, concentration and stability can be very well measured these days, even 
in complex biological fluids, a method to accurately quantify the number of nucleic acid 
therapeutics encapsulated in nanocarriers is still missing. Here we present a method, based on 
concentration measurements with Single Particle Tracking microscopy, with which it is 
possible to directly measure the number of plasmid DNA molecules per nanoparticle, referred 
to as the plasmid/NP ratio. Using DOTAP/DOPE liposomes as model carrier, we demonstrate 
the usefulness of the method by investigating the influence of various experimental factors on 
the plasmid/NP ratio. We find that the plasmid/NP ratio is inversely proportional with the size 
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of the pDNA and that the plasmid/NP decreases when lipoplexes are prepared at lower 
concentrations of pDNA and nanocarrier, with values ranging from 6.5 to 3 plasmid/NP. 
Furthermore, the effect of pre- and post-PEGylation of lipoplexes was examined, finding that 
pre-PEGylation results in a decreased plasmid/NP ratio, while post-PEGylation did not alter the 
plasmid/NP ratio. These proof-of-concept experiments show that Single Particle Tracking 
offers an extension of the nanoparticle characterization toolbox, and is expected to aid in the 
efficient development of nanoformulations for nucleic acids based therapies. 
KEYWORDS SPT, nanocarrier, liposomal gene delivery, nucleic acid delivery 
ABBREVIATIONS  
CCM, Cell Culture Medium; Ceramide-PEG2000, N-octanoyl-sphingosine-1-
[succinyl[methoxy(polyethylene glycol)2000]]; DOPE, 1,2-Dioleoyl-sn-glycero-3-
phosphoethanolamine; DOTAP, (2,3-Dioleoyloxy-propyl)-trimethylammonium-chloride; 
DSPE-PEG2000 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-(methoxy 
(polyethyleneglycol)-2000); LPX, Lipoplexes; NA, Nucleic acid; pDNA, Plasmid DNA; PEG, 
Polyethylene glycol; Plasmid/NP ratio, the average number of complexed plasmids for every 
nanocomplex; SPT, Single Particle Tracking. 
 
INTRODUCTION 
Nucleic acid biopharmaceuticals present a tremendous potential for treatment of life-
threatening and incurable diseases. DNA vaccines, siRNA and gene–based treatments are 
attracting an ever-growing interest, although delivering these nucleic acid molecules to the 
desired cells is not an easy task. The human body has evolved to resist against organisms whose 
main purpose is to insert nucleic acids into the cells of our body. To reach the desired target, 
the therapeutic nucleic acids need to overcome numerous in vivo extracellular and intracellular 
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barriers. Just to name a few, they have to cross multiple tissues (mucus and extracellular 
matrices), evade the immune system, remain intact in a nuclease rich environment, reach the 
target cell and enter the cytoplasm or nucleus1. To be able to survive such a long and perilous 
journey, therapeutic nucleic acids require a safe, biocompatible carrier that protects and delivers 
them to the target cells. As a consequence, over time studies focusing on engineering gene 
delivery systems have increased exponentially. Liposomes, cationic polymers, nanogels, 
inorganic and magnetic particles, as well as cell penetrating peptides have been studied at 
length1-7. During development they are thoroughly characterized in terms of size, surface 
charge, stability and tendency to adsorb proteins. 
A typical route to incorporate nucleic acid (NA) molecules into nanocarriers is by 
electrostatic complexation. Cationic carriers are mixed with the negatively charged nucleic 
acids at a certain charge ratio to form stable complexes. While the charge ratio between both is 
easily calculated, typically it is not known how many nucleic acid copies are present per 
nanocarrier. Yet, even at a fixed charge ratio, it is quite plausible that differences in the 
complexation conditions, such as the volume in which the complexes are prepared, may 
introduce differences on the loading degree per nanocarrier, which in turn may influence the 
final effectivity of the nanoformulation. Being able to know and consequently manipulate the 
number of therapeutic molecules per carrier may prove beneficial for rational optimization of 
the preparation method to ensure maximal effectivity. However, determining the number of NA 
copies in nanoparticles is not easily accomplished. One strategy based on single molecule 
photobleaching has been proposed8, 9, but it requires a very low background noise and single 
fluorophore detection sensitivity. Moreover, care must be taken to ensure that every nucleic 
acid molecule is labeled with one and only one fluorophore, next to the fact that this method is 
only suited for a very small number of cargo molecules per nanoparticle as bleach steps of 
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individual fluorophores have to be resolved. Indeed, for larger numbers of molecules these 
small changes in fluorescence intensity will drown in the overall shot noise. 
To address this need, here we propose a new approach to determine the number of DNA 
copies in nanoparticles. It is based on single particle tracking (SPT) microscopy with which 
nanoparticle number concentrations can be accurately determined10-14. In brief, the Brownian 
motion of individual nanoparticles is imaged, and the frequency of entering and leaving the 
focal plane is used as a fundamental metric from which the absolute nanoparticle number 
concentration, that is the number of nanoparticles in a given volume, can be determined. In this 
paper, we demonstrate that by making use of SPT concentration measurements it is possible to 
determine the number of DNA copies per nanoparticle as follows. As a first step, the pDNA 
number concentration of a pDNA solution is measured, which can be done either by SPT or by 
classic absorbance measurements. The pDNA is subsequently mixed with the carrier material 
to form nanocomplexes. Next, the number concentration of the formed DNA-carrier complexes 
is measured with SPT. Upon full complexation of the pDNA, the ratio of the two quantities 
gives the average number of plasmids for every nanoparticle, referred to in this paper as the 
plasmid/NP ratio.  
To demonstrate the proof-of principle, we focus on cationic DOTAP:DOPE liposomes as 
carriers for pDNA complexation, which have been frequently evaluated for gene therapy15-17. 
The interested reader is referred to excellent reviews for more information on this carrier system 
for gene therapy 1, 18, 19. We use the described SPT methodology to investigate how pDNA size, 
lipoplex (LPX) charge ratio and concentration at which LPX are prepared influence the number 
of pDNA copies per lipoplex. Also, on the carrier side, we investigate the influence of pre- or 
post-PEGylation of the LPXs on the number of pDNA copies per nanoparticle. Taken together 
we demonstrate that SPT concentration measurements present a unique method to precisely 
determine the average number of plasmids per nanoparticle for a given nanoformulation. This 
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new type of information is expected to contribute to the rational optimization of gene complexes 
for improved gene delivery.  
EXPERIMENTAL SECTION 
Preparation of liposomes 
(2,3-Dioleoyloxy-propyl)-trimethylammonium-chloride (DOTAP) and 1,2-Dioleoyl-sn-
glycero-3-phosphoethanolamine (DOPE) were purchased from Corden Pharma LLC (Liestal, 
Switzerland).  
1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-(methoxy(polyethyleneglycol)-2000) 
(DSPE-PEG2000) and N-octanoyl-sphingosine-1-{succinyl[methoxy(polyethylene 
glycol)2000]} (Ceramide-PEG2000) were purchased from Avanti Polar Lipids (Alabaster, AL, 
USA). The appropriate amount of the lipids (28 µl DOTAP and 29.8 µl DOPE) was mixed at a 
1:1 ratio in a round-bottom flask and dissolved in 1000 µl of chloroform (Sigma Aldrich, 
Bornem, BELGIUM). PEGylated liposomes were prepared by adding the desired amount of 
DSPE-PEG2000 or Ceramide-PEG2000, corresponding to 3 mol% or 10 mol% of the total lipids. 
The flask was then placed into the rotavapor (IKA, Staufen, Germany) and put in contact with 
a water bath pre-heated at 40°C. The pressure was reduced to 0.1 bar and the flask was rotated 
at 180 rpm for 15-20 min. The dried lipid film was then rehydrated in 0.2 ml distilled water and 
detached from the glass walls using glass pearls. The obtained liposome suspension had a 
concentration of 5 mM DOTAP and 5 mM DOPE. Since, at neutral pH, 1 mole of DOTAP has 
1 mole of positive charges, the suspension had 5 mM of positive charges. The liposome 
suspension was then placed into a 0.5 ml vial and pulse-sonicated (10 s on, 15 s off) for 6 cycles 
using a probe sonicator (Branson Ultrasonics Digital Sonifier, Danbury, USA). The size and 
zeta-potential of the liposomes were checked using the Zetasizer Nano-ZS (Malvern, 
Worcestershire, UK). Depending on the batch, liposomes had a size between 65 nm and 75 nm 
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in diameter with a PDI that was always smaller than 0.25 and a zeta-potential of around +45 
mV for the cationic liposomes and around +7 mV for the PEGylated liposomes.  
Preparation of pDNA  
Two types of plasmid DNA were used, gWizTM pDNA (≈ 5800 bp) and pBlueScript KS+ 
pDNA (≈ 3000 bp). The plasmids are multiplied in E.coli bacteria (Genlantis, San Diego, CA, 
USA) in a sterile LB-medium (NaCl; Sigma-Aldrich, St Louis, Missouri, USA / Yeast extract; 
Lab M, Heywood, UK / Tryptone; Lab M, Heywood, UK) to which the antibiotic Kanamycin 
(Sigma-Aldrich, St Louis, Missouri, USA) is added and the bacteria were incubated overnight 
at 37°C, shaken at 300 rpm. We used the QIAGEN plasmid purification protocols (QIAGEN, 
Hilden, Germany) to obtain a purified pDNA solution. The purity and concentration of the 
solution was assessed using Nanodrop 2000C (ThermoFisher Scientific, Waltham, USA ). The 
pDNA was labelled with CyTM5 (Label IT® Nucleic Acid Labeling Kits, Mirus Bio LLC, 
Madison, USA) by using 1 µl of Label IT Reagent for every 2 µg of pDNA. pDNA was purified 
from non-conjugated CyTM5 using the provided G50 Microspin Purification columns (Mirus, 
Madison, USA), as described by the manufacturer.  
Lipoplex formation and plasmid/NP experiment  
LPXs were formed by mixing, in equal volumes, a fixed amount of 1 µg of labeled pDNA 
with RNase free water and a solution with the appropriate amount of liposomes to reach the 
desired charge ratio of N/P 6, 8, 10 and 12. The lipoplex solution, which had a total volume of 
20 µl, was then vortexed and placed in the dark at room temperature for 30 minutes, to allow 
complex formation. The pDNA concentration of the solution was 50 ng/µl. Afterwards, the 
solution was diluted to a pDNA concentration of 0.3 ng/µl and the LPX concentration was 
measured with SPT. Variations in this protocol were introduced to monitor the influence on the 
resulting plasmid/NP ratio. In one set of experiments, the charge ratio was adapted by changing 
the amount of pDNA in the solution, while keeping the amount of lipids fixed at 1.2 mM 
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positive charges. In another set of experiments, both the pDNA and the liposome solutions were 
diluted ten and fifty times, respectively, before complex formation, to study the role of the 
concentration in LPX formation. In other words, the volumes of the pDNA and liposome 
solutions that were mixed together were increased 10 and 50 times, while keeping the charge 
ratio constant (at N/P 8). The undiluted, 10 and 50 times diluted stock solutions used for 
complex formation are referred to as 50 ng/µl, 5 ng/µl and 1 ng/µl respectively, based on the 
pDNA concentration.  
Also PEGylated lipoplexes were included in this study, formed by adding the desired amount 
of PEG (linker chain: DSPE or Ceramide) to the DOTAP and DOPE in the round-bottom flask 
(pre-insertion technique) or to the LPX solution after complexation (post-insertion technique). 
In the latter case, the solution was vortexed and maintained 1 h at 37°C under continuous 
stirring at 200 rpm. 
Gel Electrophoresis  
Complexation of pDNA with liposomes was verified using gel electrophoresis. 400 ng 
labeled pDNA/eppendorf was complexed with the appropriate amount of liposomes to reach 
the desired charge ratio (4, 6, 8, 10 or 12) and water was added to a total volume of 15 µl. Then 
5 µl TBE buffer (Tris; Merck Millipore, Billerica, Massachusetts, USA / Borate; VWR, 
Haasrode, Belgium / EDTA; Merck KGaA, Darmstadt, Germany) and 5 µl Loading buffer 
(ThermoFisher Scientific, Waltham, USA) were added to each solution. The samples were 
loaded on a 0.7% agarose gel (ThermoFisher Scientific, Waltham, USA) and left to run at 100 
V for 50 min. Results are shown in Fig. 1 SI and 2 SI. 
Measuring Nanoparticle Number Concentrations by Single Particle Tracking 
Single Particle Tracking is a well-known advanced microscopy technique that allows to 
analyze the mobility of nanoparticles. Briefly, SPT captures the motion of individual particles 
in time-lapse videos, which are then analyzed to reconstruct the trajectories of each of these 
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nanoparticles. From the analysis of the trajectories it is possible to calculate for instance the 
diffusion coefficient of each nanoparticle. Recently we developed a dedicated algorithm that 
allows to extract the absolute number concentration from SPT videos of nanoparticles diffusing 
freely in a liquid10, 20. The number concentration is the average number of particles identified 
per frame divided by the detection volume V. As SPT is a microscopy based method, the lateral 
dimensions of V are simply the field of view of the microscope, which is easily calibrated with 
a graded ruler. The difficulty, however, is to precisely determine the effective axial dimension, 
which is unknown and impossible to calibrate a priori since it depends on several parameters, 
including the image processing settings used to detect the particles. It can, however, be derived 
from the time particles spend inside V, which can be measured directly from the SPT movies. 
Small and fast moving particles will spend less time within V as compared to larger and slower 
ones. Thus, thanks to the fact that the diffusion coefficient can be directly measured from SPT 
data and by making use of the statistical model reported by Roding et al.10, the axial dimension 
of V can be readily determined for each SPT movie and used to calculate the absolute number 
concentration of the particles in the dispersion. 
The plasmid/NP ratio, which is of interest in this study, is then simply calculated by dividing 
the concentration of pDNA in the solution before complexation by the concentration of LPX 
after complexation, with the assumption that all the plasmid DNA is complexed. 
For every data point, a minimum of 20 videos is recorded, which all together provides a 
minimum of 1000 trajectories per data point. Every batch is tested 4 times, while every 
experiment is repeated 3 times, to ensure the validity of the results.  
RESULTS 
Validation 
First we evaluated if SPT is able to correctly measure pDNA and LPX concentration. A 
solution of gWiz™ pDNA was prepared at a concentration of 166 ± 3 ng/µl, corresponding to 
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2.84 ± 0.05*1013 pDNA strands per ml. While SPT can be operated in light scattering mode, 
the best sensitivity is obtained in combination with fluorescence. Therefore, the experiments 
reported here were all done in fluorescence mode, with pDNA labelled covalently with a far-
red fluorophore, Cy5, for optimal visualization with SPT. A dilution series was prepared from 
the stock solution at sufficiently low concentrations (0.006%, 0.013%, 0.019%, 0.025%, 
0.032%) so that the diffusion of individual pDNA copies can be imaged with SPT. The pDNA 
number concentrations as measured with SPT are presented in Fig. 1A. A linear trend line 
through the data extrapolated to 100% predicts a pDNA stock concentration of 2.66 ± 0.23*1013 
plasmid/ml, with an R2 of 0.989, in excellent agreement with the actual concentration reported 
above. This shows that SPT is well suited to measure the number concentration of Cy5-labelled 
pDNA.  
Next, we evaluated whether SPT allows to determine the number concentration of 
DOTAP:DOPE LPX containing Cy5-labelled pDNA. A dilution series was prepared from a 
LPX formulation (charge ratio of 8) and measured with SPT, as shown in Fig. 1B. Charge ratio 
8 was chosen to ensure complete complexation of the cargo while keeping the amount of carrier 
to a minimum to reduce cytotoxicity as much as possible in case the lipoplexes would be used 
for cell transfections. As expected, the LPX number concentration follows a linear trend, with 
an R2 of 0.985. From the linear fit the LPX stock concentration is extrapolated to be 1.9 ± 
0.1*1011 particle/ml.  
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Fig. 1. SPT number concentration measurements of a dilution series of (A) Cy5-labelled gWiz 
pDNA and (B) DOTAP:DOPE LPX containing Cy5-pDNA at a charge ratio of 8.  
Knowing the number concentration of plasmids and LPX, the average number of plasmids 
per LPX now readily follows from the ratio ܥ௣஽ே஺/ܥ௅௉௑. The pDNA solution, when complexed 
with DOTAP:DOPE liposomes, was diluted 20 times. Thus, for the above mentioned LPX of 
charge ratio 8 it yields a plausible number of 7.0 ± 0.7 plasmids per LPX. This result is based 
on the assumption that all pDNA is complexed (i.e. no remaining free pDNA). Based on gel 
electrophoresis this is the case here, as no uncomplexed pDNA could be detected (see SI). 
Further on we will discuss how the method can be extended in the future to also deal with 
partially uncomplexed pDNA.  
Influence of plasmid size 
As a first application of the method we investigated if the number of plasmid/NP is influenced 
by the size of the plasmid, keeping the charge ratio constant. We prepared LPX at charge ratio 
8 with gWizTM pDNA (≈ 5800 bp) and pBlueScript KS+ pDNA of about half the size (≈ 3000 
bp). 50 ng/µl pDNA was added to DOTAP:DOPE liposomes corresponding to 1.2 mM positive 
charges. As can be seen in Fig. 2A we find that 2.2 ± 0.2 times as many plasmids per LPX are 
found for the smaller pDNA, which corresponds well with the difference in size of both 
plasmids. In any case it shows that the plasmid size can influence the number of plasmid/NP.  
Influence of the concentration of pDNA and liposomes 
Next, we explicitly investigate the influence of both pDNA and liposomes concentration on 
the number of plasmid copies per LPX. LPXs were prepared at a constant charge ratio 8 for 
different concentrations of pDNA and liposomes. Fig. 2B confirms that the plasmid/NP ratio is 
highly dependent on the concentration of the initial stock solutions that are mixed when the 
LPXs are prepared. At a pDNA concentration of 1 ng/µl the LPXs contain only 3 copies of 
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pDNA, while it is about 6.5 at a concentration of 50 ng/µl. This again shows that the plasmid/NP 
ratio has the tendency to increase at higher concentrations of the interaction partners. 
Surprisingly, the LPX size showed the opposite trend, indicating that size alone is not sufficient 
to infer if LPXs have more or less copies of pDNA per particle. 
Influence of charge ratio 
To investigate how the number of plasmid/NP changes for various LPX charge ratios, we 
first start by keeping the concentration of lipids constant at 1.2 mM and adjust the amount of 
gWizTM pDNA to obtain charge ratios of 6, 8, 10 and 12 (see ‘Fixed Lipid Content’ in Table 
1). All solutions are prepared in a constant total volume of 20 µl. The results in Fig. 2C (light 
gray bars) show a clearly decreasing trend for the plasmid/NP ratio at increasing charge ratio, 
with values ranging from 10.5 ± 0.6 plasmid/NP (charge ratio 6) to 5.7 ± 0.3 plasmid/NP 
(charge ratio 12). To test if the reported values are statistically different, an unpaired t-test was 
conducted to compare the values of charge ratio 6 to the values of charge ratio 8, 10 and 12. In 
the last two cases the values are significantly different (p< 0.05), while it is not the case between 
charge ratio 6 and 8 (p = 0.07). 
The decreasing trend could be explained by the fact that the same amount of liposomes are 
available at higher charge ratios to complex less pDNA, so that it seems reasonable that 
complexes will be formed with less pDNA per particle. Although not very pronounced, this is 
to some extent also reflected in the LPX size as measured by SPT shown in Fig. 2C (light gray 
line), with about 20% decrease in size between charge ratio 6 and 12. 
Alternatively, these data can be interpreted from the pDNA point of view, demonstrating that 
more pDNA per particle is captured when a higher pDNA starting concentration is used (for 
the lowest charge ratio).  
The same charge ratio series can also be obtained by keeping the pDNA concentration 
constant at 50 ng/µl and adjusting the amount of lipids instead. In this case we find a slightly 
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increasing trend for the plasmid/NP ratio as the charge ratio increases (Fig. 2C, dark gray bars), 
with values ranging from 7.7 ± 0.2 plasmid/NP (charge ratio 6) to 9.4 ± 0.5 plasmid/NP (charge 
ratio 12). At the same time a moderate size increase is observed ( Fig. 2C, dark gray line).  
An unpaired t-test comparing the values of charge ratio 6 to the values of charge ratio 8, 10 
and 12 shows that the values are significantly different in all three cases (p < 0.05). An important 
difference with the previous charge ratio series is that the number concentration of pDNA and 
lipids is different, as seen in Table 1.  
PDNA AND LIPOSOMES CONCENTRATION 
 
CHARGE 
RATIO 
Fixed Lipid Content  Fixed pDNA Content 
Concentration 
pDNA [ng/μl] 
Concentration 
lipids [mM] 
Concentration 
pDNA [ng/μl] 
Concentration 
lipids [mM] 
6  67  1.2  50  0.9 
8  50  1.2  50  1.2 
10  40  1.2  50  1.5 
12  33  1.2  50  1.8 
Table 1. Concentration of plasmid DNA and lipids, expressed in ng/µl and nM of positive 
charges respectively, in the LPX dispersions. The volume was always kept constant at 20 µl. 
“Fixed lipid content” corresponds to 1.2 mM of lipids, and “fixed pDNA content” corresponds 
to 50 ng/µl pDNA. 
For instance for the charge ratio of 12 we now have 50% more lipids and pDNA as compared 
to the previous series. This means that the complexes are now formed at a higher concentration, 
which apparently leads to larger complexes containing more pDNA per particle. On the 
contrary, for a charge ratio of 6 we now have 25% less lipids and pDNA as in the previous 
series, which leads to smaller complexes with less pDNA per particle. Therefore, it is clear that 
the plasmid/NP ratio is not only determined by the charge ratio, but also by the concentration 
at which the complexes are prepared, as was observed in Fig. 2B.  
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Fig. 2. The effect of pDNA size, LPX charge ratio and pDNA concentration on the number of 
plasmids per LPX. (A) Effect of plasmid size on plasmid/NP ratio. Halving the number of base 
pairs in the plasmid doubles the plasmid/NP ratio, that goes from 6.4 ± 0.2 plasmids/NP to 14.1 
± 0.8 plasmids/NP. (B) Effect of concentration on the plasmid/NP ratio. Both the pDNA and 
the liposome solutions were diluted ten and fifty times (pDNA concentrations from 50 ng/μl to 
5 ng/µl and 1 ng/µl) to form LPXs at a fixed charge ratio of 8. The decrease in plasmid/NP ratio 
confirms that the complexation is concentration-dependent. (C) Plasmid/NP ratio in function of 
charge ratio. LPXs were complexed in a fixed volume (20 µl) by keeping the amount of 
plasmids constant at 50 ng/µl (dark gray) or by keeping the amount of lipids constant at 1.2 mM 
(light gray). 
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PEGylated lipoplexes 
PEGylation of nanoparticles is a common strategy to improve their transport and stability in 
biological tissues. For instance, it can prevent mucoadhesion21 and increases the nanoparticle 
half-life and colloidal stability in biofluids22, 23. However, PEG chains may also reduce the 
interaction strength between pDNA and liposomes, which in turn could affect the plasmid/NP 
ratio. Here, we investigate this for two common PEGylation strategies. In the first PEGylation 
approach, referred to as PRE-PEGylation, PEGylated lipids are added to the lipid mixture of 
the liposomes in the round-bottom flask, before water is added to form liposomes, thus before 
complexation with pDNA21, 24, 25. In the second strategy the PEG chains are added to the LPX 
dispersion after formation of the complexes, referred to as POST-PEGylation21, 25, 26. We used 
DSPE-PEG2000 and tested the effect of PRE- and POST-PEGylation, as well as the influence of 
the amount of PEG on the plasmid/NP ratio of LPXs (at fixed charge ratio 8). The graph shown 
in Fig. 3 indicates a substantial drop in the plasmid/NP ratio of PRE-PEGylated LPXs as the 
amount of PEG increases (from 6.4 ± 0.2 to 3.5 ± 0.1 to 1.8 ± 0.2 plasmid/NP). An unpaired    
t-test comparing the values of non-PEGylated complexes to the values of PRE-PEGylated 
complexes shows that the means are significantly different in all cases (p < 0.05). The 
substantial drop in plasmid/NP ratio can be explained by the steric hindrance of the PEG chains 
and the shielding of cationic charges due to which the interaction with pDNA is reduced. At the 
same time the LPX size increased, again showing that LPX size alone cannot be used to infer 
the plasmid/NP ratio. POST-PEGylation, on the other hand, did not have such a strong impact 
on the plasmid/NP ratio with only a very small reduction in the number of plasmid/NP, that 
from 6.4 ± 0.2 plasmid/NP is reduced to 5.0 ± 0.1 and 5.6 ± 0.2 plasmid/NP. This is likely due 
to the fact that the LPX are already formed at the time that the DSPE-PEG is added so that 
(most of) the pDNA remains stably incorporated. An unpaired t-test comparing the values of 
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non-PEGylated complexes to the values of POST-PEGylated complexes shows that the means 
are significantly different in all cases in which DSPE is used as a linker chain (p < 0.05), while. 
Finally, we tested if the anchor lipid that is used to post-functionalize LPX with PEG may 
have an influence. Therefore, we evaluated POST-PEGylation with 10 mol% of Ceramide-
PEG2000 instead of DSPE-PEG. Ceramide-PEG is sometimes preferred to enhance the 
interaction with the anionic cellular membrane as it is less stably incorporated into LPX as 
compared to DSPE-PEG23, 27. Post-PEGylation with Ceramide-PEG again had no influence on 
the plasmid/NP ratio compared to the non-pegylated LPX ( p = 0.36), showing that it influences 
LPX composition even less than DSPE-PEG.  
 
Fig. 3. Influence of PRE- and POST-PEGylation on the number of plasmid copies per LPX. 
Liposomes were PRE-PEGylated by incorporation of the indicated percentage of PEGylated 
DSPE lipids. POST-PEGylation of LPX was performed with both DSPE-PEG and Ceramide 
C8-PEG. All LPX were prepared at a charge ratio of 8.  
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DISCUSSION 
To obtain a safe and efficient delivery of nucleic acid-based therapeutics, a complete and 
thorough characterization of the carrier-cargo complex is required. The efficiency of the carrier 
in encapsulating or complexing the therapeutic cargo molecules is an important parameter that 
may influence the effectiveness of the carrier. To our knowledge, we present here the first 
reported method for directly measuring the plasmid/NP ratio in a flexible manner. Another 
reported method makes use of photobleaching to count the number of therapeutic molecules 
each labelled with a single fluorophore. When continuously excited, the fluorophores will 
photobleach one after the other, resulting in a step-wise decrease in intensity. By counting the 
number of steps it is possible to calculate the amount of cargo molecules in the complex. 
Importantly, this method requires each NA to be labelled with exactly one fluorophore. While 
there are methods to do that, such as the in vitro incorporation of modified nucleotides in the 
polynucleotide backbone, or the introduction of specific sequences in the plasmid DNA to allow 
sequence-specific fluorophore attachment28, these are rather complex procedures and need to 
be considered carefully. Another limitation of the method is that it is inherently limited to a low 
number of molecules, because else the step-wise decrease in fluorescence is buried in the 
overall shot-noise. Instead, our approach based on SPT nanoparticle concentration 
measurements, does not pose any particular limit on the number of plasmids per nanoparticle. 
While in principle it does not require the nucleic acids to be labelled when operated in light 
scattering mode, we did label the plasmids in our study as it improves the detection sensitivity. 
In any case, the labelling requirements are not as stringent as in the photobleaching method 
since the number of fluorophores per plasmid does not need to be controlled. Indeed, the only 
requirement is that the plasmids and complexes are visible in the SPT microscope. The 
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downside, however, is that only the average number of plasmid/NP is obtained, while the 
photobleaching methods yield information on a single particle basis. 
As a case study, we focused on DOTAP:DOPE liposomes as a model carrier and studied its 
plasmid/NP ratio for a variety of conditions. The influence of pDNA size, charge ratio of the 
LPXs and concentration of pDNA vs. liposomes were thoroughly investigated. Remarkably, 
each of those factors had an influence on the number of plasmids per carrier. First it was noted 
that LPXs formed with pDNA of half the size had double the amount of plasmids per LPX when 
prepared at the same charge ratio. It must be noted that by halving the size of the pDNA while 
keeping the weight concentration (in ng/µl) constant, the actual number of pDNA molecules 
doubled. This is exactly as one would expect and provides a validation of the proposed method. 
Then a slight decrease in plasmid/NP ratio was noticed when the charge ratio was increased by 
keeping constant the amount of lipids and varying the pDNA concentration, while the opposite 
trend was observed when the charge ratio was modified by keeping the concentration of pDNA 
constant and adjusting the amount of liposomes. Finally, we observed that preparing lipoplexes 
of fixed charge ratio at lower concentrations of pDNA and liposomes reduces the plasmid/NP 
ratio.  
In general, these observations indicate that the charge ratio itself is not the main factor that 
influences the number of plasmid per carrier, but it seems that this number also depends on the 
potential collisions between the plasmids and the liposomes. Indeed, the plasmid/NP ratio per 
nanoparticle substantially increases when the concentration of the nanocarriers constituents 
increases and/or when the pDNA size is decreased, leading to a higher amount of pDNA 
molecules for the same weight concentration.  
It should be noted that to calculate the number of pDNA per nanoparticle, the empty 
liposomes that did not bind fluorescent pDNA remain invisible for the SPT instrument. Also, 
we cannot determine how many liposomes come together to form a lipoplex with the pDNA. 
18 
 
All observations above, however, point out that it is mainly the concentration of the pDNA 
solution that dictates the plasmid/NP ratio, with more plasmid/NP when a higher pDNA starting 
concentration is used. This also points to the fact that complexation is a very fast process, as 
the amount of pDNA in the microenvironment seems to determine the amount of plasmid/NP, 
and not the overall ratio of pDNA and liposomes for which one could expect that similar ratios 
should be obtained when a large enough equilibration time is allowed. Based on our direct 
experience and the works of Pires et al.29 and Balbino et al.30, we expect complexation to happen 
in the first few seconds to minutes. Since we allowed 30 min of complexation before measuring 
the LPX concentration, the equilibrium has already been reached. Therefore we conclude that 
when the number of plasmid/NP decreases, this indicates that the complexation conditions 
helped the spreading of pDNA among the otherways uncomplexed liposomes, or vice versa, 
when the plasmid/NP increases, there are more uncomplexed liposomes in the suspension (or 
more liposomes fused together to form the complexes). 
Another factor that we investigated was the influence of PEGylation on the plasmid/NP ratio. 
Functionalization of nanoparticles with PEG chains to improve their colloidal stability in 
buffers and biofluids, and to prolong their circulation time in vivo has been widely studied21, 22, 
24, 31. Here we evaluated the effect of PEGylation on the number of plasmids per LPX and this 
revealed that the PEGylation method does have a significant impact. With PRE-PEGylated 
liposomes a decrease in the plasmid/NP ratio was observed with increasing PEG content. 
Instead, POST-PEGylation of LPX had virtually no effect on the incorporated number of 
plasmids per nanoparticle. This is most likely due to the fact that PRE-PEGylated liposomes 
have better colloidal stability, so that they have less tendency to agglomerate when the pDNA-
LPX complexes are formed. As a result those LPX will contain less liposomes per NP, also 
leading to the complexation of less pDNA per LPX. Also, the PEG-chains shield the surface 
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charge of the liposomes and provide steric hindrance, most likely lowering the affinity of pDNA 
for the liposomes. 
Optimization of nanoparticles for nucleic-based therapy should not focus only on the 
optimization of the carrier, but also of the carried nucleic acid molecules. As shown in Fig. 2A, 
the lower the number of base pairs, the higher the number of plasmids per particle. A smaller 
size is not only beneficial in the complexation process, but also during transfection. It has been 
reported that plasmid DNA bigger than 6000 bp have a substantially decreased expression 
compared to smaller constructs32. It is believed that this size-dependent reduced efficiency is 
due to the lower mobility big plasmid DNA experience in the cytoplasm. Minicircle DNAs are 
the perfect solution for an optimized transfection efficiency. Minicircle DNAs are non-viral 
closed circular gene expressing vectors to which all the sequences not directly linked to gene 
transfection are removed. They are smaller and safer than the commonly used plasmids, since 
the sequence coding for antibiotic resistance is removed, and present longer gene expression 
due to the removal of their bacterial origin of replication32, 33.  
On the technological side, while we used a custom-built program to analyze SPT data in this 
study, it is of note that SPT instruments are also commercially available, like those from 
Malvern (NanoSight) and ParticleMetrix. They are gaining in popularity for nanoparticle 
characterization to complement DLS measurements. As such the reported method should find 
easy entrance in the nanomedicine community. For optimal accuracy we do advise though to 
make use of our reported concentration algorithms which were extensively validated to give 
correct absolute concentration values in a calibration-free manner10-12, 14. 
A current limitation of the method as reported here is that it requires complete complexation 
of the cargo and its carrier. Indeed, in case there is still free pDNA in the LPX dispersion, the 
visible particles in the SPT images cannot be unambiguously assigned to LPX so that its 
concentration cannot be reliably determined. A workaround could be to label the carrier with a 
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different fluorophore so that LPX can be identified as particles having both colors while 
uncomplexed pDNA would only have one color. An alternative approach is to quantify and 
remove uncomplexed DNA by adding nucleases to the LPX sample after measuring its apparent 
concentration. The protocol would then require to measure the particle concentration two times, 
before and after the addition of DNase I. The unbound DNA can thus be quantified as the 
difference between the particle concentration in the LPX solution (CNC), measured before the 
addition of DNase I, and the LPX concentration CLPX, measured after degradation of pDNA by 
the DNase. Thus the number of plasmids per particle in this case can be calculated from 
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where CpDNA is the concentration of pDNA in the solution, complexed and unbound, and must 
be measured or calculated before complexation with the carriers.  
Finally, it is important to note that the presented SPT method is not limited to plasmids, but 
could be used for other and smaller nucleic acids as well. The only requirements are that (1) the 
concentration of nucleic acids is known or can be measured precisely beforehand, (2) that 100% 
complexation is obtained, and (3) that the final complexes can be visualized by SPT (scattering 
or fluorescence). Furthermore, in case the (liposomal) carrier would be labeled, the same SPT 
method could be used to determine the carrier number concentration, which would allow to get 
even more detailed insight into the formation and composition of pDNA-carrier complexes. 
CONCLUSION 
Prior to fulfilling their therapeutic effect, nucleic acid/carrier complexes must overcome 
numerous barriers that vary according to the administration route. To exploit their full potential, 
such nanomedicines must be extensively characterized. However, differences in the 
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complexation conditions, such as pDNA size, concentration of the components and type of 
protocol used to PEGylate the nanoparticles, introduce differences on the loading degree per 
nanoparticle. In future research it is of interest to investigate for lipoplexes but also for other 
carriers how that may influence the biological effectivity of the formulation. We have proposed 
to take advantage of SPT nanoparticle concentration measurements and apply it to determine 
the number of plasmids per nanoparticle, a type of characterization that was not possible before. 
Given the fact that SPT instruments are commercially available and are increasingly being used 
for nanoparticle characterization, we believe that the demonstrated method can find rapid 
acceptance in the field and contribute to the development of safer and more efficient 
nanoformulations for nucleic acids based-therapies.  
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FIGURE CAPTION 
Fig. 1. SPT number concentration measurements of a dilution series of (A) Cy5-labelled gWiz 
pDNA and (B) DOTAP:DOPE LPX containing Cy5-pDNA at a charge ratio of 8.  
Fig. 2. The effect of pDNA size, LPX charge ratio and pDNA concentration on the number of 
plasmids per LPX. (A) Effect of plasmid size on plasmid/NP ratio. Halving the number of base 
pairs in the plasmid doubles the plasmid/NP ratio, that goes from 6.4 ± 0.2 plasmids/NP to 14.1 
± 0.8 plasmids/NP. (B) Effect of concentration on the plasmid/NP ratio. Both the pDNA and 
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the liposome solutions were diluted ten and fifty times (pDNA concentrations from 50 ng/μl to 
5 ng/µl and 1 ng/µl) to form LPXs at a fixed charge ratio of 8. The decrease in plasmid/NP ratio 
confirms that the complexation is concentration-dependent. (C) Plasmid/NP ratio in function of 
charge ratio. LPXs were complexed in a fixed volume (20 µl) by keeping the amount of 
plasmids constant at 50 ng/µl (dark gray) or by keeping the amount of lipids constant at 1.2 mM 
(light gray). 
Fig. 3. Influence of PRE- and POST-PEGylation on the number of plasmid copies per LPX. 
Liposomes were PRE-PEGylated by incorporation of the indicated percentage of PEGylated 
DSPE lipids. POST-PEGylation of LPX was performed with both DSPE-PEG and Ceramide 
C8-PEG. All LPX were prepared at a charge ratio of 8.  
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